1
|
Wang W, Gao T, Luo J, Guo L, Li X, Li Y, Chen H. Size distribution analysis of residual host cell DNA fragments in lentivirus by CGE-LIF. Electrophoresis 2023; 44:462-471. [PMID: 36353919 DOI: 10.1002/elps.202200218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 11/02/2022] [Accepted: 11/02/2022] [Indexed: 11/12/2022]
Abstract
During the production of cell and gene therapy products, residual host cell DNA (HCD) could cause safety risks of the biological products, and the longer the residual HCD fragment, the greater the risk to the human body. For this reason, it was necessary to develop an effective method for the size distribution analysis of residual HCD fragments with high accuracy and sensitivity. In this study, capillary gel electrophoresis with laser-induced fluorescence detector (CGE-LIF) was used to analyze the size distribution of residual HCD fragments in lentivirus products. The results confirmed that lentiviral RNA genome could interfere with the size distribution analysis of residual HCD fragments. By optimizing the amount of RNase I and digestion time in sample pretreatment process, the interfere of RNA genome could be avoided. The specificity, precision, accuracy, linear range, the detection of limit (LOD), and the quantification of limit (LOQ) of CGE-LIF method were also validated. The results showed that the CGE-LIF method had a good performance both in terms of specificity and reproducibility. The intra- and inter-day relative standard deviations of migration time and corrected peak area were all less than 1% and 2%, respectively. The 200 bp DNA marker had a good linearity between 50 and 1000 pg/ml. The LOD and LOQ of 200 bp DNA marker were 2.59 and 8.64 pg/ml, respectively. In addition, this method was successfully used to analyze the size distribution analysis of residual HCD fragments in lentivirus products with different production processes.
Collapse
Affiliation(s)
| | | | - Ji Luo
- SCIEX, Beijing, P. R. China
| | | | - Xiang Li
- Division of Recombinant Biological Products, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China
| | - Yan Li
- National Medical Products Administration (NMPA), Key Laboratory for Quality Control and Evaluation of Vaccines and Biological Products, SiChuan Institute for Drug Control, Chengdu, P. R. China
| | | |
Collapse
|
2
|
Luo H, Li Y, Robbins D, Wang SC, Xi G, Cox M, Nicholson SM, Wei C, Pabst TM, Wang WK. Safety risk management for low molecular weight process-related impurities in monoclonal antibody therapeutics: Categorization, risk assessment, testing strategy, and process development with leveraging clearance potential. Biotechnol Prog 2020; 37:e3119. [PMID: 33373106 PMCID: PMC8365748 DOI: 10.1002/btpr.3119] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 12/04/2020] [Accepted: 12/20/2020] [Indexed: 11/12/2022]
Abstract
Process-related impurities (PRIs) derived from manufacturing process should be minimized in final drug product. ICH Q3A provides a regulatory road map for PRIs but excludes biologic drugs like monoclonal antibodies (mAbs) that contain biological PRIs (e.g. host cell proteins and DNA) and low molecular weight (LMW) PRIs (e.g., fermentation media components and downstream chemical reagents). Risks from the former PRIs are typically addressed by routine tests to meet regulatory expectations, while a similar routine-testing strategy is unrealistic and unnecessary for LMW PRIs, and thus a risk-assessment-guided testing strategy is often utilized. In this report, we discuss a safety risk management strategy including categorization, risk assessment, testing strategy, and its integrations with other CMC development activities, as well as downstream clearance potentials. The clearance data from 28 mAbs successfully addressed safety concerns but did not fully reveal the process clearance potentials. Therefore, we carried out studies with 13 commonly seen LMW PRIs in a typical downstream process for mAbs. Generally, Protein A chromatography and cation exchange chromatography operating in bind-and-elute mode showed excellent clearances with greater than 1,000- and 100-fold clearance, respectively. The diafiltration step had better clearance (greater than 100-fold) for the positively and neutrally charged LMW PRIs than for the negatively charged or hydrophobic PRIs. We propose that a typical mAb downstream process provides an overall clearance of 5,000-fold. Additionally, the determined sieving coefficients will facilitate diafiltration process development. This report helps establish effective safety risk management and downstream process design with robust clearance for LMW PRIs.
Collapse
Affiliation(s)
- Haibin Luo
- Purification Process Sciences, Biopharmaceutical Development Department, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, USA
| | - Yuling Li
- Purification Process Sciences, Biopharmaceutical Development Department, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, USA
| | - David Robbins
- Purification Process Sciences, Biopharmaceutical Development Department, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, USA
| | - Sheau-Chiann Wang
- Analytical Sciences, Biopharmaceutical Development Department, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, USA
| | - Guoling Xi
- Purification Process Sciences, Biopharmaceutical Development Department, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, USA
| | - Matthew Cox
- Purification Process Sciences, Biopharmaceutical Development Department, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, USA
| | - Simone M Nicholson
- Safety Science, Biopharmaceutical Development Department, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, USA
| | - Chenghong Wei
- Regulatory Affairs, Biopharmaceutical Development Department, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, USA
| | - Timothy M Pabst
- Purification Process Sciences, Biopharmaceutical Development Department, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, USA
| | - William K Wang
- Purification Process Sciences, Biopharmaceutical Development Department, Biopharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, USA
| |
Collapse
|
3
|
Faya P, Sondag P, Novick S, Banton D, Seaman JW, Stamey JD, Boulanger B. The current state of Bayesian methods in nonclinical pharmaceutical statistics: Survey results and recommendations from the DIA/ASA-BIOP Nonclinical Bayesian Working Group. Pharm Stat 2020; 20:245-255. [PMID: 33025743 DOI: 10.1002/pst.2072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 08/26/2020] [Accepted: 09/06/2020] [Indexed: 11/07/2022]
Abstract
The use of Bayesian methods to support pharmaceutical product development has grown in recent years. In clinical statistics, the drive to provide faster access for patients to medical treatments has led to a heightened focus by industry and regulatory authorities on innovative clinical trial designs, including those that apply Bayesian methods. In nonclinical statistics, Bayesian applications have also made advances. However, they have been embraced far more slowly in the nonclinical area than in the clinical counterpart. In this article, we explore some of the reasons for this slower rate of adoption. We also present the results of a survey conducted for the purpose of understanding the current state of Bayesian application in nonclinical areas and for identifying areas of priority for the DIA/ASA-BIOP Nonclinical Bayesian Working Group. The survey explored current usage, hurdles, perceptions, and training needs for Bayesian methods among nonclinical statisticians. Based on the survey results, a set of recommendations is provided to help guide the future advancement of Bayesian applications in nonclinical pharmaceutical statistics.
Collapse
Affiliation(s)
- Paul Faya
- Statistics-Discovery/Development, Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Perceval Sondag
- Center for Mathematical Sciences, Merck & Co., Inc, Kenilworth, New Jersey, USA
| | - Steven Novick
- Department of Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA
| | - Dwaine Banton
- Translational Medicine and Early Development Statistics, Janssen, Raritan, New Jersey, USA
| | - John W Seaman
- Department of Statistical Science, Baylor University, Waco, Texas, USA
| | - James D Stamey
- Department of Statistical Science, Baylor University, Waco, Texas, USA
| | - Bruno Boulanger
- PharmaLex Statistical Solutions, Mont-Saint-Guibert, Belgium
| |
Collapse
|
4
|
Liu XZ, Zhang B, Zhao W, Li G, Zhou ML, Wei JS, Zhou JH, Gao J, Wang ZM. Method validation of Q-PCR detection of host residual DNA in antibody drug based on protein A magnetic beads. Biologicals 2019; 62:65-71. [DOI: 10.1016/j.biologicals.2019.09.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 09/05/2019] [Accepted: 09/06/2019] [Indexed: 01/26/2023] Open
|
5
|
Development of an in-House TaqMan Real-Time PCR-Based Method to Detect Residual Host Cell DNA in HBV Vaccine. Appl Biochem Biotechnol 2016; 179:375-82. [PMID: 26861732 DOI: 10.1007/s12010-016-2000-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Accepted: 01/27/2016] [Indexed: 12/20/2022]
Abstract
Biological therapeutic products such as recombinant hepatitis B virus (HBV) vaccine, produced by microbial fermentation in complex media, should be evaluated for host cell DNA contamination in purification steps. Eliminating these contaminations increases the efficacy of the vaccine and decreases its side effects. The objective of the present study is to trace the residual host cell DNA (HCD) in recombinant HBV vaccine by developing a TaqMan Real-Time PCR method which is more sensitive, specific, and reproducible than traditional methods such as Picogreen analysis and Threshold DNA assay. Primers and a probe were designed for the most highly conserved regions of Pichia pastoris genome. To determine the specificity of the assay, in addition to performing a BLAST for the primers and the probe in NCBI nucleotide database, 20 different human genomes and 8 bacterial and viral genomes were used. Moreover, serial dilutions of plasmids, from 10(2) to 10(7) copies/μL (from 0.00064 to 6.4 pg/μL), were prepared to find the sensitivity and the limit of detection (LOD) of the assay. Using 28 different genome samples, the specificity of the assay was determined to be 100 %. In addition, the sensitivity and LOD of the method was 0.39 × 10(-5) pg/μL. Moreover, the reproducibility of the assay based on intra- and inter-assay was 1.03 and 1.06 %, respectively. Considering the suitable specificity and sensitivity, ease of use, relatively low cost, and rapidity of the assay, it can be a reproducible and sensitive method to examine recombinant vaccines for P. pastoris residual DNA.
Collapse
|